SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects
NCT05215808
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
72
Enrollment
INDUSTRY
Sponsor class
Conditions
Atopic Dermatitis
Interventions
DRUG:
RBN-3143
Sponsor
Ribon Therapeutics, Inc.